ArticleVaccine2016
Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022Review
- A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.Frontiers in microbiology · 2022Article
- Non-human primate models of human respiratory infections.Molecular immunology · 2021Review
- Genetic diversity and molecular evolution of human respiratory syncytial virus A and B.Scientific reports · 2021Article
- Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2.Epigenomics · 2020Review
- Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Human Metapneumovirus: A Largely Unrecognized Threat to Human Health.Pathogens (Basel, Switzerland) · 2020Article
- Self-Replicating RNA Viruses for RNA Therapeutics.Molecules (Basel, Switzerland) · 2018Review
- Prophylactic and therapeutic approaches for human metapneumovirus.Virusdisease · 2018Review
- Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.Journal of virology · 2018Article
- Human metapneumovirus - what we know now.F1000Research · 2018Review
- Animal models of respiratory syncytial virus infection.Vaccine · 2017Review
- Alphavirus Replicon DNA Vectors Expressing Ebola GP and VP40 Antigens Induce Humoral and Cellular Immune Responses in Mice.Frontiers in microbiology · 2017Article
- Replicon RNA Viral Vectors as Vaccines.Vaccines · 2016Review
- Modulation of Host Immunity by the Human Metapneumovirus.Clinical microbiology reviews · 2016Review
- Clinical Insights and Advancements in Human Metapneumovirus Management and Prognosis.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) are major causes of illness among children, the elderly, and the immunocompromised. No vaccine has been licensed for protection against either of these viruses. We tested the ability of two Venezuelan equine encephalitis virus-based viral replicon particle (VEE-VRP) vaccines that express the hRSV or hMPV fusion (F) protein to confer protection against hRSV or hMPV in African green monkeys. Animals immunized with VEE-VRP vaccines developed RSV or MPV F-specific antibodies and serum neutralizing activity. Compared to control animals, immunized animals were better able to control viral load in the respiratory mucosa following challenge and had lower levels of viral genome in nasopharyngeal and bronchoalveolar lavage fluids. The high level of immunogenicity and protective efficacy induced by these vaccine candidates in nonhuman primates suggest that they hold promise for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.